201 related articles for article (PubMed ID: 28961836)
21. Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer.
Wong SJ; Moughan J; Meropol NJ; Anne PR; Kachnic LA; Rashid A; Watson JC; Mitchell EP; Pollock J; Lee RJ; Haddock M; Erickson BA; Willett CG
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):116-23. PubMed ID: 25446610
[TBL] [Abstract][Full Text] [Related]
22. Preoperative Chemoradiation With VMAT-SIB in Rectal Cancer: A Phase II Study.
Picardi V; Macchia G; Guido A; Giaccherini L; Deodato F; Farioli A; Cilla S; Compagnone G; Ardizzoni A; Cuicchi D; Gambacorta MA; Cellini F; Frezza G; Poggioli G; Valentini V; Fuccio L; Morganti AG
Clin Colorectal Cancer; 2017 Mar; 16(1):16-22. PubMed ID: 27435759
[TBL] [Abstract][Full Text] [Related]
23. Preoperative chemoradiotherapy with capecitabine and triweekly oxaliplatin versus capecitabine monotherapy for locally advanced rectal cancer: a propensity-score matched study.
Li A; Huang T; Zheng R; Chi P; Li Z; Wang X; Xu B
BMC Cancer; 2022 Jul; 22(1):789. PubMed ID: 35850711
[TBL] [Abstract][Full Text] [Related]
24. Influence of concurrent capecitabine based chemoradiotherapy with bevacizumab on the survival rate, late toxicity and health-related quality of life in locally advanced rectal cancer: a prospective phase II CRAB trial.
Velenik V; Zadnik V; Omejc M; Grosek J; Tuta M
Radiol Oncol; 2020 Aug; 54(4):461-469. PubMed ID: 32738130
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in MRI-Defined Locally Advanced T3 Resectable Rectal Cancer: Final Results of a Randomized, Noncomparative Phase 2 INOVA Study.
Borg C; Mantion G; Boudghène F; Mornex F; Ghiringhelli F; Adenis A; Azria D; Balosso J; Ben Abdelghani M; Bachet JB; Vendrely V; François Y; Conroy T; Rio E; Roullet B; Spaëth D; Quero L; Lakkis Z; Coudert M; Ionescu-Goga M; Tanang A; André T
Clin Colorectal Cancer; 2019 Sep; 18(3):200-208.e1. PubMed ID: 31311761
[TBL] [Abstract][Full Text] [Related]
26. Interim analysis of postoperative chemoradiotherapy with capecitabine and oxaliplatin versus capecitabine alone for pathological stage II and III rectal cancer: a randomized multicenter phase III trial.
Feng YR; Zhu Y; Liu LY; Wang WH; Wang SL; Song YW; Wang X; Tang Y; Liu YP; Ren H; Fang H; Zhang SP; Liu XF; Yu ZH; Li YX; Jin J
Oncotarget; 2016 May; 7(18):25576-84. PubMed ID: 27014909
[TBL] [Abstract][Full Text] [Related]
27. Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study.
Eisterer W; Piringer G; DE Vries A; Öfner D; Greil R; Tschmelitsch J; Samonigg H; Sölkner L; Gnant M; Thaler J;
Anticancer Res; 2017 May; 37(5):2683-2691. PubMed ID: 28476845
[TBL] [Abstract][Full Text] [Related]
28. Results in the elderly with locally advanced rectal cancer from the ACCOR12/PRODIGE 2 phase III trial: tolerance and efficacy.
François E; Azria D; Gourgou-Bourgade S; Jarlier M; Martel-Laffay I; Hennequin C; Etienne PL; Vendrely V; Seitz JF; Conroy T; Juzyna B; Gerard JP
Radiother Oncol; 2014 Jan; 110(1):144-9. PubMed ID: 24418359
[TBL] [Abstract][Full Text] [Related]
29. Prospective phase II trial of neoadjuvant chemo-radiotherapy with Oxaliplatin and Capecitabine in locally advanced rectal cancer (XELOXART).
Ricardi U; Racca P; Franco P; Munoz F; Fanchini L; Rondi N; Dongiovanni V; Gabriele P; Cassoni P; Ciuffreda L; Morino M; Filippi AR; Aglietta M; Bertetto O
Med Oncol; 2013; 30(2):581. PubMed ID: 23606239
[TBL] [Abstract][Full Text] [Related]
30. HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab.
Sclafani F; Roy A; Cunningham D; Wotherspoon A; Peckitt C; Gonzalez de Castro D; Tabernero J; Glimelius B; Cervantes A; Eltahir Z; Oates J; Chau I
Ann Oncol; 2013 Dec; 24(12):3123-8. PubMed ID: 24146218
[TBL] [Abstract][Full Text] [Related]
31. Preoperative chemoradiotherapy with capecitabine and oxaliplatin in locally advanced rectal cancer. A phase I-II multicenter study of the Dutch Colorectal Cancer Group.
Hospers GA; Punt CJ; Tesselaar ME; Cats A; Havenga K; Leer JW; Marijnen CA; Jansen EP; Van Krieken HH; Wiggers T; Van de Velde CJ; Mulder NH
Ann Surg Oncol; 2007 Oct; 14(10):2773-9. PubMed ID: 17653805
[TBL] [Abstract][Full Text] [Related]
32. Phase II Trial Using a Combination of Oxaliplatin, Capecitabine, and Celecoxib with Concurrent Radiation for Newly Diagnosed Resectable Rectal Cancer.
Araujo-Mino EP; Patt YZ; Murray-Krezan C; Hanson JA; Bansal P; Liem BJ; Rajput A; Fekrazad MH; Heywood G; Lee FC
Oncologist; 2018 Jan; 23(1):2-e5. PubMed ID: 29158365
[TBL] [Abstract][Full Text] [Related]
33. Preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with newly diagnosed, primary operable, cT₃NxM0, low rectal cancer: a phase II study.
Ofner D; Devries AF; Schaberl-Moser R; Greil R; Rabl H; Tschmelitsch J; Zitt M; Kapp KS; Fastner G; Keil F; Eisterer W; Jäger R; Offner F; Gnant M; Thaler J;
Strahlenther Onkol; 2011 Feb; 187(2):100-7. PubMed ID: 21267531
[TBL] [Abstract][Full Text] [Related]
34. Preoperative chemotherapy in patients with intermediate-risk rectal adenocarcinoma selected by high-resolution magnetic resonance imaging: the GEMCAD 0801 Phase II Multicenter Trial.
Fernandez-Martos C; Brown G; Estevan R; Salud A; Montagut C; Maurel J; Safont MJ; Aparicio J; Feliu J; Vera R; Alonso V; Gallego J; Martin M; Pera M; Sierra E; Serra J; Delgado S; Roig JV; Santos J; Pericay C
Oncologist; 2014 Oct; 19(10):1042-3. PubMed ID: 25209376
[TBL] [Abstract][Full Text] [Related]
35. Comparison of Capecitabine (Xeloda) vs. Combination of Capecitabine and Oxaliplatin (XELOX) as Neoadjuvant CRT for Locally Advanced Rectal Cancer.
Yaghobi Joybari A; Azadeh P; Babaei S; Hosseini Kamal F
Pathol Oncol Res; 2019 Oct; 25(4):1599-1605. PubMed ID: 30712194
[TBL] [Abstract][Full Text] [Related]
36. Long-course neoadjuvant chemoradiotherapy with versus without a concomitant boost in locally advanced rectal cancer: a randomized, multicenter, phase II trial (FDRT-002).
Wang J; Guan Y; Gu W; Yan S; Zhou J; Huang D; Tong T; Li C; Cai S; Zhang Z; Zhu J
Radiat Oncol; 2019 Nov; 14(1):215. PubMed ID: 31783766
[TBL] [Abstract][Full Text] [Related]
37. Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial.
Allegra CJ; Yothers G; O'Connell MJ; Beart RW; Wozniak TF; Pitot HC; Shields AF; Landry JC; Ryan DP; Arora A; Evans LS; Bahary N; Soori G; Eakle JF; Robertson JM; Moore DF; Mullane MR; Marchello BT; Ward PJ; Sharif S; Roh MS; Wolmark N
J Natl Cancer Inst; 2015 Nov; 107(11):. PubMed ID: 26374429
[TBL] [Abstract][Full Text] [Related]
38. Comparative effectiveness of postoperative chemotherapy among older patients with non-metastatic rectal cancer treated with preoperative chemoradiotherapy.
Lund JL; Sturmer T; Sanoff HK
J Geriatr Oncol; 2016 May; 7(3):176-86. PubMed ID: 26926829
[TBL] [Abstract][Full Text] [Related]
39. Retrospective study of preoperative chemoradiotherapy with capecitabine versus capecitabine plus oxaliplatin for locally advanced rectal cancer.
Yang XH; Li KG; Wei JB; Wu CH; Liang SX; Mo XW; Chen JS; Tang WZ; Qu S
Sci Rep; 2020 Jul; 10(1):12539. PubMed ID: 32719436
[TBL] [Abstract][Full Text] [Related]
40. Patients with pathological stage N2 rectal cancer treated with early adjuvant chemotherapy have a lower treatment failure rate.
Feng YR; Jin J; Ren H; Wang X; Wang SL; Wang WH; Song YW; Liu YP; Tang Y; Li N; Liu XF; Fang H; Yu ZH; Li YX
BMC Cancer; 2017 Mar; 17(1):182. PubMed ID: 28279170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
